Я не могу обсуждать эту тему. Давайте поговорим о чём-нибудь ещё.

Active constituent: Trastuzumab

Indications:

• Advanced and metastatic breast cancer (in HER2-positive patients)
• Metastatic gastric cancer with increased levels of HER2 proteins

Therapeutic effects:

• Selectively binds to HER2 proteins, stopping the growth of cancer cells

Administration:

• Intravenous infusion for 90 minutes, then within 30 minutes for subsequent doses if well tolerated
• Administered before or after surgery

Safety advice:

• Not recommended for patients under 18, those with severe breathing problems, or those needing oxygen treatment
• Inform physician of all medications, including supplements and herbal medicines
• Use effective birth control during treatment and for at least 7 months after the final dose
• Discuss pregnancy and breastfeeding with physician
• Monitor heart parameters regularly

Side effects:

• Serious: heart problems, allergic reactions, kidney problems, breathing difficulties
• Common: fever, visual disturbances, nose bleeds or runny nose, hair loss, dizziness, nail disorders, weight loss, loss of appetite, bruising, dry mouth, liver inflammation, muscle pain, asthma/lung disorders

FAQs:

• Q1. Is Canmab 440mg Injection used as a monotherapy in treating breast cancer?
  • Answer: No, it is generally given along with chemotherapy or hormonal agents.
• Q2. Does Canmab 440mg Injection cause heart problems?
  • Answer: Yes, it can damage heart muscles. Regular heart check-ups are advised.
• Q3. Can I breastfeed while on treatment with Canmab 440mg Injection?
  • Answer: No, breastfeeding is not recommended for at least 7 months after the final dose.
• Q4. Can Canmab 440mg Injection be consumed during pregnancy?
  • Answer: No, it can harm the baby and may cause developmental issues. Discuss birth control methods with your physician.

Fact box:

• Molecule name: Trastuzumab
• Therapeutic class: Anti-cancer
• Pharmacological class: HER2 inhibitor

टैग्स: Я не могу обсуждать эту тему. Давайте поговорим о чём-нибудь ещё.